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Abstract The urokinase receptor (uPAR) on the cell surface
plays an important role in extracellular proteolysis, cell
migration and adhesion. Soluble uPAR (suPAR) has been
recently discovered in plasma, but its origin is unclear. Our
results now demonstrate that both unstimulated blood mono-
nuclear and endothelial cells can release suPAR and that the
release is enhanced when either mononuclear cells or thrombo-
cytes are cultured together with endothelial cells. Co-culture
without cell^cell contacts fails to enhance suPAR release. We
also found suPAR fragments, known to be potent inducers of
chemotaxis, in co-culture growth medium samples. Taken
together, our results suggest that normal plasma suPAR can be
produced by endothelial and mononuclear cells and that suPAR
release in cell^cell contacts may have a regulatory role in cell
adhesion. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The urokinase-type plasminogen activator (uPA)-mediated
plasminogen activation cascade has been shown to be impor-
tant in extracellular proteolysis in normal physiology and can-
cer pathophysiology [1]. However, in recent years, growing
evidence has suggested that uPA and its high-a⁄nity cell sur-
face receptor (uPAR) are not only important in proteolytic
events, but have an equally important role in cell migration,
adhesion and chemotaxis [2^4].
uPAR is bound to the cell surface via a glycosylphosphati-
dylinositol (GPI) anchor and consists of three homologous
domains (D1^D3), which have di¡erent binding properties
for various ligands [5]. With its amino-terminal D1 domain,
uPAR binds uPA, whereas domains 2+3 (D2D3) are impor-
tant in vitronectin binding [6]. The full-size receptor, however,
is needed for high-a⁄nity interactions [7,8]. Several enzymes,
including uPA and plasmin, are capable of cleaving uPAR
between domains 1 and 2+3 [9,10]. Yet, the physiological
enzyme responsible for cleavage of the whole receptor from
the cell surface has remained unclear, although in vitro results
have suggested that GPI-speci¢c phospholipase D may cata-
lyze receptor shedding from the cell surface [11]. Several mem-
bers of L1-, L2- and L3-integrin families have also been asso-
ciated with uPAR, indicating its strong involvement in cell
adhesion [2,12,13].
In body £uids, such as plasma, urine and ascitic £uid, a
soluble form of uPAR (suPAR) has been discovered in recent
years [14^18]. In healthy individuals, plasma suPAR levels are
quite low [15]. However, in cancer patients, suPAR levels are
elevated at diagnosis [18^20] and they are also associated with
poor survival prognosis in leukemia [20] and in ovarian and
colon cancer [18,19]. Furthermore, our studies in leukemia
have shown that plasma suPAR levels decrease rapidly during
chemotherapy concomitantly with the disappearance of tumor
cells [21], suggesting that tumor cells produce plasma suPAR.
However, in healthy individuals, the origin of plasma suPAR
and the physiological events leading to its release from the cell
surface have remained obscure. We have therefore studied the
shedding of uPAR from endothelial and leukocyte cell surfa-
ces under physiological conditions and the presence of suPAR
and various uPAR fragments in the growth media of these
cells. In addition, we have analyzed the e¡ect of cell^cell in-
teractions on suPAR release in co-culture experiments.
2. Materials and methods
2.1. Materials
Anti-uPAR antibodies (R2, R3 and R4) were kindly provided by
Dr. Gunilla HÖyer-Hansen (Finsen Laboratory, Copenhagen, Den-
mark). Cell culture growth medium RPMI 1640, fetal bovine serum
(FBS), glutamine, penicillin and streptomycin were purchased from
Gibco-BRL (Karlsruhe, Germany). Transwell co-culture plates were
from Costar (Corning Inc., Corning, NY, USA) and Ficoll-Paque
from Amersham Pharmacia (Uppsala, Sweden). Protease inhibitor
tablets (Complete1) and immobilized streptavidin were from Boehr-
inger Mannheim (Mannheim, Germany). BCA protein assay kit and
chemiluminescent substrate (SuperSignal Ultra) were from Pierce
(Rockford, IL, USA).
2.2. General cell cultures
Human microvascular endothelial cells (HMEC-1) [22], kindly pro-
vided by Dr. T.J. Lawley (Emory University School of Medicine,
Atlanta, GA, USA), were grown in RPMI 1640 in the presence of
10% FBS containing 2 mM glutamine, 100 IU/ml penicillin and 100
Wg/ml streptomycin. Peripheral blood mononuclear cells and throm-
bocytes were separated by Ficoll-Paque centrifugation from EDTA
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blood of healthy donors. After separation, the cells were washed twice
with phosphate-bu¡ered saline (PBS) and suspended in RPMI 1640.
Puri¢ed thrombocytes were also obtained from the Finnish Red Cross
Blood Transfusion Service (Helsinki, Finland). Only freshly isolated
cells were used.
2.3. Co-cultures
Endothelial cells (105 cells/0.4 ml of growth medium) were seeded in
48-well plates and left to form monolayers overnight at +37‡C in a
humidi¢ed 5% CO2 atmosphere. The next morning, the growth me-
dium was removed, and freshly isolated blood mononuclear cells
(2.5U105 cells/0.4 ml of growth medium) or thrombocytes were added
either to the endothelial cells or directly to empty wells. After 4, 8, 12,
24, 48 and 72 h of culture, the growth media were collected, centri-
fuged and stored frozen until assay.
Cells were also co-cultured in Transwell plates (12-well plate, poly-
carbonate membrane with 0.4 Wm pore size). Endothelial cells
(2.5U105/ml) were grown in the lower chamber and mononuclear cells
(6.3U105/ml) or thrombocytes were added either to the lower cham-
ber on the endothelial cells to allow for cell^cell contacts or into the
upper chamber of the same wells to share of the growth medium
without cell^cell contacts. Growth media were collected at 1^3 days
of culture. Cells were counted from di¡erent wells after growth me-
dium collection, and the number of cells was found to be equal in the
di¡erent experimental settings.
Blood mononuclear cells were removed from the co-culture after 3
days. After washings, the endothelial cells were harvested from the
culture plates with cell scrapers and lysed in PBS containing 1% Tri-
ton X-100 and protease inhibitors (Complete1). The lysates were kept
on ice for 1 h, centrifuged for 10 min at 14 000Ug at 4‡C, and the
supernatants were stored at 370‡C until assay. The amount of total
protein was determined by the BCA protein assay kit.
2.4. Incubation of peripheral blood
Peripheral citrated or heparinized whole blood was obtained from
healthy volunteers. Immediately after the collection and after 1, 2 and
3 days of incubation on a rotator at 4‡C or at 37‡C, the plasma was
separated by centrifugation for 30 min at 4‡C at 1800Ug and stored
frozen in aliquots at 370‡C until analysis.
2.5. Assay of soluble uPAR and uPAR in cell lysates
The uPAR enzyme-linked immunosorbent assay (ELISA) has been
described previously [15]. It uses a polyclonal rabbit anti-human
uPAR as a catching antibody and a mixture of monoclonal antibodies
(R2, R3 and R5) as detecting antibodies. 1:2 dilutions of growth
media, 1:10 dilutions of plasma samples and a volume equal to
20 Wg of protein from the cell lysates were used in the ELISA.
2.6. Immunoprecipitation and immunoblotting
The methods for immunoprecipitation and immunoblotting have
been described previously [23]. In brief, growth media and cell lysate
samples were immunoprecipitated with biotinylated R2 and R3 mono-
clonal antibodies prebound to immobilized streptavidin. Immunopre-
cipitated proteins were fractionated by 12% SDS^PAGE under non-
reducing conditions. The proteins were transferred to nitrocellulose
membranes and detected with polyclonal rabbit anti-uPAR IgG,
with chemiluminescent visualization of the complexes.
2.7. Immuno£uorescence staining
Cells were grown on glass coverslips in multi-well culture plates.
After culturing, plates were transferred on ice, and cells on the cover-
slips were washed twice with Dulbecco’s balanced salt solution sup-
plemented with 0.5% bovine serum albumin. After washings, mono-
clonal anti-uPAR antibodies (R4) (10 Wg/ml) or control antibodies
were added on coverslips and incubated for 30 min on ice, after which
cells were washed again. Before secondary antibody addition, cells
were ¢xed with ice-cold methanol for 15 min at 320‡C, followed by
thorough washings and incubation with secondary FITC-conjugated
antibodies. Finally, cells were washed again, and coverslips were
mounted on microscope slides.
2.8. Statistical analysis
Results are reported as mean þ S.E.M. Student’s unpaired and
paired t-tests were used for comparison of results. Results were con-
sidered signi¢cant when P = 0.05.
3. Results
3.1. Secretion of suPAR by cultured endothelial cells and blood
mononuclear cells
Both endothelial and blood mononuclear cells are candidate
sources of the plasma suPAR, because they are known to
express uPAR. Therefore, we wanted to analyze the release
of suPAR by these cells and by freshly isolated thrombocytes
in normal cell culture conditions. Our results demonstrate that
both unstimulated endothelial cells and peripheral blood
mononuclear cells are able to secrete small amounts of suPAR
(0.48 and 0.13 ng/106 cells, respectively, in 24 h) into their
growth medium (Fig. 1A). Lysates of these cells also con-
tained uPAR as detected with uPAR ELISA and with immu-
noprecipitation followed by immunoblotting. In contrast, pu-
ri¢ed fresh thrombocytes did not contain any uPAR and
neither did they secrete suPAR (Fig. 1B), and even after stim-
ulation with phorbol 12-myristate 13-acetate (PMA) or adher-
ence to collagen, no suPAR was detected in their growth
medium (results not shown).
We also incubated citrated or heparinized whole blood
Fig. 1. Secretion of suPAR by endothelial cells and blood cells in
culture. Freshly isolated, unstimulated peripheral blood mononu-
clear cells (PBMC) (A) or thrombocytes (THR) (B) were cultured
either alone or with endothelial cells (END) in normal cell culture
conditions. Samples of growth media were collected at 4, 8, 12, 24,
48 and 72 h of culture, and suPAR levels were measured with
uPAR ELISA. Shown are the mean þ S.E.M. values from three sep-
arate experiments.
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from healthy individuals on a rotator at 4 or 37‡C to see if
blood cells can release suPAR in ex vivo conditions. When
blood was incubated at physiological temperature (37‡C) al-
lowing normal cell functions, a signi¢cant increase in the plas-
ma suPAR level was already seen after 1 day of incubation
(1.32 þ 0.21 vs. 0.71 þ 0.12 ng/ml basal level ; P6 0.02, paired
t-test) and a further increase to 1.93 þ 0.19 ng/ml after 3 days
of incubation (P6 0.001, paired t-test). No signi¢cant change
in suPAR level was observed in blood incubated at 4‡C.
3.2. Higher amounts of suPAR in the growth media of
endothelial cells co-cultured with blood mononuclear cells
or with thrombocytes
In circulation, blood cells are in close contact with endo-
thelial cells, and prior to extravasation, leukocytes need to
adhere to endothelial cells. Therefore, we wanted to study
the production of suPAR in co-cultures and grew endothelial
and blood mononuclear cells either together or alone. From
these cultures, growth media were collected at 4, 8, 12, 24, 48
and 72 h. After 24 h, the suPAR level was already signi¢-
cantly increased in endothelial cell+blood mononuclear cell
co-culture media as compared with growth media in which
either endothelial cells or mononuclear cells had grown alone,
and a similar trend was observed in samples collected at 48
and 72 h (Fig. 1A). After 72 h, suPAR levels were still quite
low in media in which either endothelial or mononuclear cells
had been grown alone (0.35 þ 0.06 and 0.24 þ 0.05 ng/ml, re-
spectively), but in co-culture media, the suPAR level
(1.07 þ 0.07 ng/ml) was double the amount expected from ad-
dition of endothelial+mononuclear cell values (Fig. 1A). The
number of cells in co-cultures was equivalent to that of cul-
tures where either cell type was grown alone.
Puri¢ed thrombocytes were similarly co-cultured with endo-
thelial cells. The amount of suPAR was already signi¢cantly
higher at 24 h (0.30 þ 0.03 ng/ml) in the co-culture growth
medium as compared with the situation where endothelial
cells were grown alone (0.09 þ 0.01 ng/ml; P6 0.01, Student’s
unpaired t-test) (Fig. 1B). In addition, no suPAR was detected
in the growth medium where thrombocytes had been cultured
alone. As already observed for mononuclear leukocytes, the
di¡erence in suPAR levels continued at 48 and 72 h of culture
(Fig. 1B).
3.3. Cell^cell contacts needed for induced suPAR secretion to
the growth medium
To examine whether cell^cell contacts were required for the
enhanced suPAR secretion to the growth medium or whether
soluble molecules in a shared growth medium were su⁄cient
to induce this synergistic e¡ect, cells were co-cultured in
Transwell chambers. When blood mononuclear cells were
grown in the upper Transwell chambers without cell^cell con-
tacts to endothelial cells in the lower chambers, the suPAR
levels in the growth medium did not di¡er notably from com-
bined suPAR values of separately growing cells (Fig. 2A).
This was even more evident in thrombocyte^endothelial cell
co-culture. When thrombocytes were cultured in the upper
chamber without cell^cell contact to endothelial cells, the su-
PAR values in the growth media were equal to the values of
endothelial cells grown alone (0.24 vs. 0.23 ng/ml after 72 h,
respectively) (Fig. 2B). In contrast, when both cells were cul-
Fig. 2. Secretion of suPAR in co-cultures. Endothelial cells (END) were co-cultured with blood mononuclear cells (PBMC) (A) or with throm-
bocytes (THR) (B) in Transwell chambers either with or without cell^cell contacts. suPAR levels were measured with uPAR ELISA and the
mean þ S.E.M. values from three separate experiments are shown. Samples of growth media were also immunoprecipitated with monoclonal
uPAR antibodies; the lower panel shows a representative immunoblotting experiment done with polyclonal uPAR antibodies. The panels
marked with an asterisk show longer exposures of co-culture growth medium samples.
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tured in contact with each other in the lower chamber, the
suPAR level was markedly increased (0.64 ng/ml), suggesting
the requirement of cell^cell contacts for the synergistic e¡ect
(Figs. 1 and 2).
3.4. Di¡erent forms of cleaved suPAR in culture medium
samples
suPAR fragments have been shown to induce chemotactic
e¡ect in vitro [3,4]. To determine the forms of suPAR antigen
and the possible presence of uPAR fragments in endothelial/
blood cell culture media, the samples were immunoprecipi-
tated with uPAR antibodies and run in SDS^PAGE. Immu-
noblotting con¢rmed the results obtained by uPAR ELISA,
and more suPAR was seen in culture media of cells in contact
with each other in co-cultures (Fig. 2). Notably, both full-
length receptor (55 kDa) and D2D3 (35 kDa) fragment were
detected. Longer exposure to chemiluminescent visualization
showed that the D1 (15 kDa) fragment was also present in
growth medium samples of cells cultured together (Fig. 2).
Interestingly, the molecular weight of suPAR in culture
medium samples of blood mononuclear cells cultured alone
seemed to be slightly higher than that of suPAR in endothelial
cell media or in co-culture growth media (Fig. 2A), suggesting
that the increased level of suPAR found in co-cultures was
derived from endothelial cells and not from mononuclear
cells.
3.5. Increased amount of uPAR in endothelial cell lysates and
increased intensity of cell surface uPAR staining in
endothelial cells co-cultured with peripheral blood cells
Most likely, in thrombocyte^endothelial cell co-cultures,
endothelial cells were responsible for the enhanced suPAR
release, because thrombocytes failed to express and release
suPAR. However, in blood mononuclear^endothelial cell co-
cultures this was unclear, because both of these cell types had
uPAR on the surface. Therefore, we examined the presence
and the amount of uPAR on endothelial cell surfaces and in
the lysates of cells cultured for 3 days either with or without
blood mononuclear cells or thrombocytes. Before making ly-
sates, the endothelial cells were washed and only a few mono-
nuclear cells or thrombocytes remained attached after wash-
ings. Equal amounts of protein of the lysates were analyzed
with uPAR ELISA and with immunoprecipitation followed
by immunoblotting. Both methods showed that increased
amounts of uPAR were present in endothelial cell lysates of
cells co-cultured either with mononuclear cells or with throm-
bocytes as compared with lysates made of endothelial cells
cultured alone (Fig. 3). Immunoblotting revealed that both
full-size uPAR and D2D3 fragments were present in endothe-
lial cell lysates, and importantly, in endothelial cell lysates co-
cultured either with mononuclear cells or with thrombocytes,
more fragmented uPAR was found (Fig. 3).
In addition, endothelial cells were cultured on glass cover-
slips with puri¢ed blood mononuclear cells or with thrombo-
cytes for 24 h, after which cells were stained with uPAR anti-
bodies. When endothelial cells were cultured alone, they
expressed small amounts of uPAR on the cell surface, and
some staining was also seen in stria-like structures (Fig. 4).
After co-culturing with mononuclear leukocytes or with
thrombocytes, the intensity of uPAR staining was markedly
higher in endothelial cells and the localization of uPAR dif-
fered in various co-cultures (Fig. 4). In co-cultures with leu-
kocytes, uPAR staining seemed to concentrate in focal adhe-
sion-like structures, whereas in thrombocyte^endothelial cell
co-cultures, staining was more di¡use (Fig. 4). Similar di¡er-
ences were also observed after 48 h of co-culturing.
Taken together, both the increased intensity of uPAR stain-
ing on the endothelial cell surfaces and increased amount of
uPAR in cell lysates suggest that the source of enhanced su-
PAR level in co-cultures is endothelial cells.
4. Discussion
This study demonstrates that both unstimulated endothelial
cells and blood mononuclear cells are able to produce suPAR
in cell culture conditions. We were also able to show that
suPAR release is enhanced in co-culture conditions when ei-
ther blood mononuclear cells or thrombocytes are cultured in
cell^cell contact with endothelial cells, while without cell^cell
contacts, induced suPAR release was not observed. In addi-
tion, the results suggest that in co-cultures the endothelial cells
are responsible for this enhanced suPAR release, as in endo-
thelial cell lysates and on the endothelial cell surface uPAR
levels were increased after co-culturing, and furthermore, be-
cause thrombocytes fail to express uPAR. Di¡erent forms of
uPAR fragments were also observed in growth medium and
cell lysate samples.
suPAR was ¢rst discovered in the ascitic £uid of ovarian
cancer patients [14], and since then, elevated levels of suPAR
have been found in plasma or serum of patients with various
types of cancer [15,16,18^20]. The origin of suPAR in cancer
Fig. 3. uPAR in endothelial cell lysates. Endothelial cells were either
cultured alone or with blood mononuclear cells (PBMC) or with
thrombocytes (THR), and cells were collected and lysed after 3 days
of culture. The upper panel shows mean uPAR levels in cell lysates
from three di¡erent experiments measured with uPAR ELISA, and
the lower panel shows a representative experiment of immunoblot-
ting of immunoprecipitated lysate samples. Equal amounts of pro-
tein were taken from each sample for ELISA (20 Wg) and immuno-
precipitation analysis (40 Wg).
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patients’ plasma has been debated, but recent reports have
shown that human suPAR can be found in the serum samples
of mice carrying human xenograft tumors [24], indicating that
the tumors are, at least partially, the source of suPAR in
plasma. In addition, our studies in leukemia patients, showing
that plasma suPAR levels correlate closely with the tumor cell
load in circulation and decrease rapidly during chemotherapy
concomitant with the disappearance of tumor cells [21], sup-
port this possibility. In normal blood cells, uPAR is expressed
in monocytes and granulocytes, but not in unstimulated lym-
phocytes or thrombocytes [25,26]. In adherent cells, uPAR is
also present in various cell types, e.g. in endothelial cells,
smooth muscle cells and keratinocytes [5]. The U937 mono-
cytic cell line has recently been shown to produce suPAR in
culture [23,27], but to our knowledge, the present report is the
¢rst demonstration that blood cells produce suPAR in the
plasma and that in normal cell culture conditions mononu-
clear cells and endothelial cells release suPAR to their growth
medium without stimulation.
Under normal physiological conditions, leukocytes circulate
in the blood without adhering to endothelial cells. When in-
£ammation or other stimuli occur, leukocytes start to adhere
to endothelial cells and after extravasation, migrate to the site
of in£ammation. On one hand, they need to adhere to endo-
thelial cells and to the extracellular matrix (ECM), but on the
other hand, they must detach to be able to move on. Notably,
our results showed that more suPAR is released to the culture
medium when cells are in physical contact with each other.
This may be a feedback mechanism for cells to control their
adherence to ECM, as uPAR has been shown to be an im-
portant adhesion receptor for vitronectin and also because
uPAR is associated with many ECM integrins [2,12,13]. Fur-
thermore, removal of uPAR from the cell surface has been
shown to prevent L2-integrin-mediated leukocyte adhesion to
Fig. 4. Expression of uPAR in endothelial cells. Endothelial cells were cultured for 24 h either alone or with peripheral blood mononuclear cells
or with thrombocytes on the glass coverslips. Cells were stained with monoclonal anti-uPAR antibodies (R4), and detection was based on im-
muno£uorescence method. Magni¢cation 500U.
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the endothelium [28]. However, if uPAR is released from the
cell surface to the growth medium, the plasminogen activation
cascade diminishes on the cell surface and cells lose part of
their proteolytic activity.
In vitro experiments have shown that recombinant suPAR
fragments and chymotrypsin-cleaved suPAR possess strong
chemotactic activity [3,4]. These fragments have now been
found in various biological £uids, e.g. urine [17,23] and ascitic
and cystic £uids of cancer patients [16]. In normal plasma,
only a full-length receptor has been found thus far, but in
leukemia patients’ plasma samples, we have also observed
cleaved suPAR [21]. Our results now indicate that suPAR
fragments occur in growth media of endothelial cells cultured
together with mononuclear cells or with thrombocytes. Fur-
thermore, fragment D1, which has thus far only been found in
urine samples and in culture media of PMA-stimulated U937
cells, was present in co-culture growth medium samples. The
reason for cleaved fragments not being observed in plasma
samples of healthy individuals may be that the half-life of
suPAR fragments is very short in circulation and that mostly
full-length receptors are released. Our experimental setting
allowing mononuclear cells to adhere to endothelial cells
may represent more closely the in vivo situation at the site
of injury or in£ammation when cells start to adhere to the
endothelium and extravasate. Based on this, it can be specu-
lated that suPAR release and especially the release of suPAR
fragments in cell^cell contacts may be a chemotactic stimulus
of these cells to recruit other cells.
Which type of cells in endothelial cell and blood mononu-
clear cell co-cultures are responsible for the enhanced suPAR
release? Our results show that after co-culturing cell surface
expression of uPAR is enhanced in endothelial cells and that
their lysates also contain more uPAR, which suggests that
endothelial cells may be activated and produce more suPAR
in the growth medium. This view is supported by thrombocyte
experiments. Earlier reports have shown that thrombocytes do
not contain uPAR [25], i.e. they are not able to secrete suPAR
either. To con¢rm that they are unable to release suPAR even
when stimulated, we treated thrombocytes with PMA or al-
lowed them to adhere to collagen, which is known to activate
thrombocytes. The thrombocytes, however, failed to produce
suPAR.
In conclusion, our results show that suPAR can be pro-
duced by endothelial cells and blood mononuclear cells in
culture, suggesting that normal suPAR found in plasma is,
at least in part, produced by these cells. Furthermore, we
have demonstrated that cell^cell contacts are needed to en-
hance suPAR release to the growth medium in endothelial^
blood cell co-cultures. However, further studies are needed to
clarify which factors in£uence suPAR shedding from the cell
surface and to learn whether suPAR has a biological role in
soluble form in the circulation.
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